Technique to make CAR T-cells in vivo could transform cancer care
In recent years, chimeric antigen receptor (CAR) T-cell therapy has changed outcomes for patients with aggressive blood cancers that no longer respond to standard treatments. In some acute leukaemias, CAR T-cell therapy has led to remissions lasting months or even years. Early-stage trials have explored its use in severe autoimmune diseases like lupus as well, … Read more